Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Galapagos NV ADR (NQ: GLPG ) 26.74 +0.03 (+0.11%) Streaming Delayed Price Updated: 4:00 PM EST, Nov 5, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Galapagos NV ADR < Previous 1 2 3 4 Next > Why Trip.com Group Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket August 27, 2024 Via Benzinga Major Investor Says Galapagos Is 'Undervalued,' Plans To Push On Company's 'Performance' And 'Strategic Opportunities' August 26, 2024 Galapagos stock rises as EcoR1 Capital discloses a 9.9% stake and plans to engage on business and governance. Investor sees shares as deeply undervalued despite challenges, with new focus on CAR-T... Via Benzinga Galapagos Surges On An FDA Win For Its Rival To Gilead, Novartis; But There Are Some Caveats August 26, 2024 The company is gearing up to rival giants Gilead and Novartis with a potentially decentralized CAR-T process. Via Investor's Business Daily Exposures Product Safety Galapagos, XPeng, CorMedix And Other Big Stocks Moving Higher On Monday August 26, 2024 Via Benzinga 8 Analysts Have This to Say About Galapagos July 17, 2023 Via Benzinga Where Galapagos Stands With Analysts June 12, 2023 Via Benzinga JP Morgan Maintains Neutral Rating for Galapagos: Here's What You Need To Know May 31, 2023 Via Benzinga Earnings Outlook For Galapagos May 03, 2023 Via Benzinga Why MIRA Pharmaceuticals Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket August 26, 2024 Via Benzinga FDA Approves Adaptimmune Therapeutics' Engineered Cell Therapy As First For Solid Tumor And New Therapy For Rare Soft Tissue Cancer In Over A Decade August 02, 2024 FDA approves Adaptimmune Therapeutics' Tecelra for unresectable or metastatic synovial sarcoma, a rare cancer near large joints. Tecelra, the first engineered cell therapy for solid tumors in the U.S.,... Via Benzinga Exposures Product Safety GLPG Stock Earnings: Galapagos Beats EPS, Beats Revenue for Q2 2024 August 01, 2024 GLPG stock results show that Galapagos beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. Via InvestorPlace GLPG Stock Earnings: Galapagos Beats EPS, Misses Revenue for Q1 2024 June 25, 2024 GLPG stock results show that Galapagos beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. Via InvestorPlace Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications May 30, 2024 Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell... Via Newsfile Earnings Preview For Galapagos February 23, 2023 Via Benzinga Where Galapagos Stands With Analysts November 07, 2022 Galapagos (NASDAQ:GLPG) has observed the following analyst ratings within the last quarter: Via Benzinga Galapagos Downgraded, Pharma Firm Faces Uphill Battle With Slow Pipeline Progress: Analyst April 01, 2024 BofA Securities downgrades Galapagos to underperform due to limited near-term catalysts and competitive challenges in crowded markets. Via Benzinga Frontier Medicines Announces Oversubscribed $80 Million Series C Financing to Support Progress of Clinical-Stage Pipeline February 22, 2024 From Frontier Medicines Via GlobeNewswire European Drugmaker Galapagos Collaborates With Biotech BridGene Biosciences To Develop Cancer Treatments January 03, 2024 On Wednesday, BridGene Biosciences Inc. announced a strategic collaboration and licensing agreement with Galapagos NV (NASDAQ: GLPG). Via Benzinga GLPG Stock Earnings: Galapagos Beats EPS, Beats Revenue for Q3 2023 December 13, 2023 GLPG stock results show that Galapagos beat analyst estimates for earnings per share and beat on revenue for the third quarter of 2023. Via InvestorPlace Benzinga's Top Ratings Upgrades, Downgrades For May 8, 2023 May 08, 2023 Via Benzinga BigCommerce, ContextLogic And Other Big Stocks Moving Lower In Friday's Pre-Market Session February 24, 2023 U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session. Via Benzinga Galapagos' Blood Cancer Candidate Shows 100% Objective Response Rate In Relapsed/Refractory Patients February 10, 2023 Via Benzinga Why Galapagos Stock Is Falling Today February 09, 2023 Galapagos NV (NASDAQ: GLPG) announced the topline results from the DIVERSITY Phase 3 trial of filgotinib during induction and maintenance treatment of biologic-naïve and biologic-experienced patients... Via Benzinga Twitter Rolls Out 'Blue For Business,' Visa Pitches Auto-Payments On Ethereum Blockchain, Justin Bieber Slams H&M: Today's Top Stories December 20, 2022 Benzinga Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For January 23, 2023 January 23, 2023 Via Benzinga On A Mission As Top European Player, Galapagos Looks For Acquisition Targets December 20, 2022 Galapagos NV (NASDAQ: GLPG) is reportedly looking for M&A deals with companies with products still in the preclinical or early stage of development. Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For November 7, 2022 November 07, 2022 Upgrades Via Benzinga After FDA, European Agency Limits Use Of Certain JAK Inhibitors Amid Safety Concerns October 31, 2022 Via Benzinga Expert Ratings for Galapagos October 13, 2022 Over the past 3 months, 4 analysts have published their opinion on Galapagos (NASDAQ:GLPG) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... Via Benzinga 3 Biotech Stocks to Sell in October September 29, 2022 These biotech stocks to sell are at a cross roads with their businesses with few growth catalysts ahead amid this turbulent market. Via InvestorPlace < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
